Background: The worldwide incidence of osteomyelitis is approximately 21.8 cases per 100,000 person-years. The cornerstone of treatment is prolonged (4-6 weeks) intravenous antibiotic administration. This entails additional cost, inconvenience, and added manpower from the healthcare system. Thus, studies have explored the possible use of oral antibiotics as alternatives to improve patient compliance and reduce costs. Our meta-analysis aimed to compare the efficacy of oral versus intravenous antibiotics in treating adult patients with osteomyelitis.

Materials and Methods: Electronic databases (PubMed, Medline, EMBASE, Cochrane Central Register of Controlled Trials, Google Scholar, and Research Gate) from 1966 to April 2020 were searched using the terms “oral antibiotics”, “osteomyelitis”, “randomized controlled trial”. Only studies that directly compared oral versus intravenous antibiotics and confirmed osteomyelitis through biopsy and/or imaging were included. Primary outcome is remission (resolution of symptoms with no relapse and bacteriologic eradication); secondary outcomes, (a) relapse (persistence of the pathogen after treatment) and (b) adverse events. The validity of included studies was assessed using the Cochrane Handbook for Systematic Reviews of Interventions. We performed a random-effects model in Review Manager Version 5.3 with 95% confidence interval. The I2 test was used to assess heterogeneity.

Results: Seven of 89 trials comprised of 1,282 patients were included in the final analysis. All studies included patients with osteomyelitis of the lower extremities. Oral antibiotics used were Ciprofloxacin, Ofloxacin, and Co-trimoxazole; intravenous antibiotics used were deemed appropriate by the infectious disease specialist. Patients were only given either oral or intravenous antibiotics. Results showed an 8% increase in remission rates [RR 1.08 (0.81 to 1.44, 95% CI, Z = 0.52, p=0.60)] with no heterogeneity (I2 = 0%) in the intravenous antibiotics group. However, this was not statistically significant. Furthermore, there was a 62% decrease in relapse rates in the intravenous antibiotics group [RR 1.62 (0.85 to 3.07, 95% CI, Z = 1.47, p = 0.14)] with no heterogeneity (I2 = 0%) but was not statistically significant.

Conclusions: Oral are comparable to intravenous antibiotics in treating osteomyelitis in terms of remission and relapse rates. However, larger and double-blinded trials should be done to generate more robust data to validate these claims.

Keywords: Oral, Intravenous, Parenteral, Osteomyelitis, Randomized Control Trials

1. Schmitt SK. Osteomyelitis. Infect. Dis. Clin. North Am. 2017 Jun;31(2):325-338.
2. Kremers HM, Nwojo ME, Ransom JE, Wood-Wentz CM, Melton LJ, Huddleston PM. Trends in the epidemiology of osteomyelitis: a population-based study, 1969 to 2009. J Bone Joint Surg Am. 2015 May 20;97(10):837-45.
3. Lew DP, Waldvogel FA. Osteomyelitis. N. Engl. J. Med. 1997 Apr 03;336(14):999-1007.
4. Euba G, Murillo O, Fernandez-Sabe N, et al. Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis. Antimicrobial agents and chemotherapy vol. 53,6 (2009): 2672-6. doi:10.1128/AAC.01504-08.
5. Gentry LO, and Rodriguez G. Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. Antimicrobial agents and chemotherapy vol. 34,1 (1990): 40-3. doi:10.1128/aac.34.1.40.
6. Gentry LO, and Rodriguez-Gomez G. Ofloxacin versus parenteral therapy for chronic osteomyelitis. Antimicrobial agents and chemotherapy vol. 35,3 (1991): 538-41. doi:10.1128/aac.35.3.538.
7. Gomis M, Barberan J, Sanchez B, et al. Oral Ofloxacin versus Parenteral Imipenem-Cilastatin in the Treatment of Osteomyelitis. Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia, U.S. National Library of Medicine, Sept. 1999, https://www.ncbi.nlm.nih.gov/pubmed/10878516.
8. Greenberg RN, Kennedy DJ, Reilly PM, et al. Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin. Antimicrobial agents and chemotherapy vol. 31,2 (1987): 151-5. doi:10.1128/aac.31.2.151.
9. Li HK, Scarborough M, Zambellas R, et al. Oral versus intravenous antibiotic treatment for bone and joint infections (OVIVA): study protocol for a randomised controlled trial. Trials. 16(583). 21 Dec. 2015, doi:10.1186/s13063-015-1098-y.
10. Mader JT, Cantrell JS, Calhoun J. Oral ciprofloxacin compared with standard parenteral antibiotic therapy for chronic osteomyelitis in adults. Journal of Bone Joint Surgery - American Volume 1990;72(1):104–10.